国内对头孢克肟的临床研究与评价

头孢克肟是第1种第3代口服头孢菌素类抗生素,由日本藤泽制药株式会社于1987年研制成功并首先在日本上市应用于临床,1989年在美国上市。1999年已在80多个国家得到广泛的临床使用。头孢克肟的制剂剂型的研究已发展有胶囊剂、颗粒剂、混悬剂、片剂(普通片剂、咀嚼片、分散片)等。笔者综述了国产头孢克肟与日本产头孢克肟在胶囊剂、颗粒剂、混悬剂、片剂(普通片剂、咀嚼片、分散片)等的药动学比较,以及头孢克肟与头孢泊肟、头孢克洛、头孢呋辛、头孢美他酯、头孢噻肟、头孢地尼、头孢特仑、头孢妥仑匹酯等体外抗菌活性及临床药效学比较。

Evaluation and Clinical Application of Cefixime in China

Cefixime is the first one of the 3 rd generation oral cephalosporin antibiotics, which Fujisawa Pharmaceutical Co., Ltd. of Japan successfully developed. It was first used clinically in Japan, in 1987, and then it was sold in the United States, in 1989. It bas been extensively used in more than 80 countries in clinical practice since 1999. Cefixime formulations have been developed into the dosage tbrms of capsules, granules, suspension, tablets （regular tablets, chewable, dispersible tablets）, etc. This article described the pharmacokinetics differences from Chinese and Japanese production of cefixime in the capsules, granules, suspension, tablets （regular tablets, chewable, dispersible tablets）, etc.. This article also described the differences of the antibacterial activity in vitro and clinical pharmacodynamics of cefixime from cefpodoxime, cefaclor, cefuroxime, cefeamet pivoxil, cefotaxime, cefdinir, cefteram, cefditoren pivoxil, etc..